Your Notifications
All done, no notifications

CAR-T Cost in Singapore

Costs starts from USD475000
Filters

How Much Does CAR-T Cost in Singapore?

The cost of CAR-T in Singapore is USD 475000

Additionally, factors like the duration of treatment, the need for follow-up care, and the use of advanced technologies or specialized treatments can further influence the overall cost.

Factors Influencing the Cost of CART:

CART is an acronym for a promising experimental type of cancer treatment called Chimeric Antigen Receptor T-cell therapy and mainly targets blood malignancies such as leukemia and lymphoma. This therapy is done by modifying the patient’s T-cells (one form of white blood cells) in the laboratory and making them have a receptor that homes in on cancerous cells. These engineered T-cells are then transduced back into the patient, they go on to hunt for cancer cells to kill.

CART therapy is rather effective, particularly in the cases of the treatment efficacy of which has not been rather impressive. It is individual treatment, which means that is independent of the cancer type in the patient. There are risks for cytokine release syndrome (CRS), as well as neurotoxicity that should be closely watched out for, but this option is hopeful for cancer patients who normally cannot be treated with conventional treatments.

Cost of CAR-T in Major Cities of Singapore

CityCost (USD)Cost (SGD)
SingaporeUSD 475000612750

CAR-T Cost : A Global Comparison

CountryMinimum CostMinimum Local CurrencyMaximum CostMaximum Local Currency
Czechiaget request
IndiaUSD 80000INR 6851200USD 120000INR 10276800
LithuaniaUSD 300000LTL 1026210USD 500000LTL 1710350
MalaysiaUSD 75000MYR 318000USD 125000MYR 530000
Saudi ArabiaUSD 373000SAR 1398750USD 500000SAR 1875000
Singapore - - USD 475000SGD 612750
SpainUSD 30000ESP 4411197USD 56000ESP 8234234
SwitzerlandUSD 373000CHF 309590USD 500000CHF 415000
ThailandUSD 150000THB 4906500USD 470000THB 15373700
TunisiaUSD 100000TND 298000USD 200000TND 596000
TurkeyUSD 25000TRY 976500USD 55000TRY 2148300
United Arab EmiratesUSD 200000AED 734000USD 300000AED 1101000
United KingdomUSD 373000GBP 276020USD 475000GBP 351500

Need Help Planning Your Treatment Abroad?

Your 24/7 AI Health Assistant

CAR T-cell therapy represents a groundbreaking approach to harnessing the power of the body's immune system to combat cancer. By modifying T cells, a subset of white blood cells, in a laboratory setting, these cells are empowered to recognize and eliminate cancer cells with precision. Often categorized as a form of cell-based gene therapy, CAR T-cell therapy involves altering the genetic makeup of T cells, equipping them with the ability to target specific cancer antigens.

This innovative treatment has demonstrated remarkable efficacy, particularly in cases where conventional therapies have proven ineffective. Its ability to reprogram the immune system to target and destroy cancer cells marks a significant advancement in cancer treatment strategies.

Classification:

CAR T cell therapy is classified as follows:

  • Structure-based classification:
  • First-generation CAR T-cells: These CAR T-cells typically consist of an antigen-binding domain (single-chain variable fragment, scFv) linked to a T-cell activation domain, such as the CD3ζ chain. They lack additional co-stimulatory domains.
  • Second-generation CAR T-cells: These CAR T-cells include an additional co-stimulatory domain, such as CD28 or 4-1BB (CD137), along with the CD3ζ chain. The presence of co-stimulatory domains enhances T-cell activation and persistence.
  • Third-generation CAR T-cells: These CAR T-cells incorporate two co-stimulatory domains along with the CD3ζ chain, aiming to further enhance T-cell function and anti-tumor activity.

Antigen-based classification: It includes

  • CD19-targeted CAR T-cells: CD19 is a common target for CAR T-cell therapy and is used in the treatment of B-cell malignancies such as acute lymphoblastic leukemia (ALL) and certain types of lymphoma.
  • Other antigen-targeted CAR T-cells: CAR T-cells can be engineered to target a variety of antigens expressed on cancer cells, including but not limited to BCMA (B-cell maturation antigen), CD22, CD30, and EGFRvIII.

CAR T-cell therapy is primarily used to treat blood cancers, such as multiple myeloma, large B-cell lymphoma, and B-cell acute lymphoblastic leukaemia. The patient's own T cells are reprogrammed to identify and destroy cancer cells, cause remission, enhance survival, and have a plan B in case other treatments fail.

Patients with blood cancers who relapsed or are refractory must consult an oncologist to determine candidacy for CAR T therapy, especially if they have failed to respond to traditional treatments (i.e., chemotherapy, radiation, or stem cell transplant). Evaluation is warranted for symptoms such as loss of weight, swelling of lymph nodes, recurrent infection, chronic fatigue, or spontaneous bruising.

Screening tests consist of imaging, bone marrow biopsy, and blood work.Leukapheresis is utilised to harvest T cells from the patient's blood for T-cell collection.Bridging therapy: Certain patients receive chemotherapy while waiting for CAR T cells to be produced.Lymphodepleting chemotherapy is administered before the injection to make room for CAR T cells. The patients should plan for potential hospitalisation, designate caretakers, and discuss long-term follow-up and expected adverse effects with the medical team.

  • T-cell harvesting: T cells are removed from the patient's blood by processing.
  • Genetic alteration: T cells are designed in the laboratory to express CAR proteins targeting cancer cells.
  • Expansion: Modified T cells are expanded to therapeutic levels.
  • Infusion: Patient receives an intravenous infusion of CAR T cells.
  • Monitoring: Intensive monitoring, often in the hospital, for side effects and reactions.

The whole process, from cell harvesting to infusion, can take three to six weeks. The infusion itself takes a few hours to a few minutes, but for at least one week following the infusion, close monitoring is required, and there will be frequent follow-ups for several months.

  • Cytokine Release Syndrome (CRS)
  • Neurotoxicity
  • Infections
  • Low blood counts
  • Relapse or non-response

One of the newer treatment options for some blood cancers is CAR T-cell therapy. It is utilised when other treatments are not working or the cancer recurs. CAR T-cell therapy has the potential to cure many blood cancers and extend life in most cases.

Recovery involves managing side effects like CRS and neurotoxicity, monitoring blood levels, and avoiding infections. Laboratory testing, imaging, and monitoring for late issues like hypogammaglobulinemia or relapse are all included in long-term follow-up.

The nature of the cancer, the burden of the disease, and an individual's response all impact success. For example, in pediatric acute lymphoblastic leukaemia, complete remission rates are more than 80%. However, relapse is always a risk, and long-term success is variable.

Would you like some help? We are available.

Get Help
Explore Hospitals ( 1 )
CAR-T in Farrer Park Hospital: Costs, Top Doctors, and Reviews

Singapore, Singapore

Apart from in-detail treatment procedures available, Farrer Park Hospital located in Connexion, Singapore has a wide variety of facilities available for International Patients. Some of the facilities which are provided by them are Accommodation, Airport Transfer, Choice of Meals, Interpreter, SIM, TV inside room. Also listed below are some of the most prominent infrastructural details:

  • A medical centre is linked to the Farrer Park Hospital Complex, Connexion, Singapore
  • The focus of the hospital is to bring together two essential elements: those of healthcare combined with hospitality.
  • There is a building with 20 different stories which comprises Owen Link, hotel and spa.
  • Personal attention and patient care focus is maintained with a system in place of listening, analysing, evaluating and then implementing a treatment plan.
  • 121 bed capacity
  • Technology and innovations help provide the best of medical and surgical treatment options.
  • Professionally implemented international patient care systems
  • Suites: Cardiovascular, day surgery, endoscopy, major surgery, nuclear medicine, radiation oncology, and inpatient suite
  • Diagnostic imaging and intensive care unit
  • 24 hour emergency clinic and pharmacy
  • Facilities such as dialysis, nutrition services, rehab centre, and teaching clinic

Need Some Advice From Our Experts?

Request a Call Back Now!

Our team of healthcare experts would be happy to assist you

trusted Patientstrusted Patients+99
Trusted by 50000+ Patients
Required | alphabets and spaces
Required | A valid, working email address
Required | A valid contact

Process Involved for CAR-T in Singapore

  • Preoperative Stage: An assessment of the patient's medical history, including testing to determine eligibility for CAR-T therapy and identify the target antigen on cancer cells.
  • Treatment Plan Discussion: An oncologist discusses the procedure of CAR-T therapy, including potential dangers, advantages, and side effects.
  • Therapeutic Stage: T-cells are extracted from the patient, modified in the lab to express a chimeric antigen receptor (CAR), and reintroduced into the patient to target and destroy cancer cells.
  • Postoperative Phase: Closely monitor for side effects. Follow-ups are scheduled regularly to check the response and treat any complications.
  • Cancer patients, especially those suffering from blood cancers like leukemia, lymphoma, and multiple myeloma.
  • Patients who have not responded to previous therapies, such as chemotherapy or radiation.
  • Patients in good overall health with a functioning immune system.
  • Individuals who have specific genetic markers that qualify them for CAR-T treatment.
  • Targeted Action: CAR-T treatment specifically targets cancer cells, increasing efficacy while minimising damage to healthy cells.
  • Potential for Remission: Can result in long-term remission, even in people with difficult-to-treat cancer.
  • Minimally Invasive: The treatment consists mainly of an outpatient procedure for T-cell collection, with the therapy provided via infusion.
  • Medical Oncologist
  • Fill out the inquiry form: Fill out the form to provide us with the relevant information about your condition.
  • Consult with Our Healthcare Expert: One of our qualified specialists will contact you for a consultation.
  • Receive a Detailed Treatment Plan: After examining your situation, we will provide you with a detailed treatment plan that includes expert views and cost breakdowns for various choices.
  • Choose your preferred option: Choose the treatment option that suits you the best.

Instantly Connect with our CAR-T Specialists

Doctor 1
Doctor 2
Doctor 3
Doctor 4
Doctor 5
Doctor 6
Doctor 7
Doctor 8
Our Services to Better your Experience

Opinion & Option

We submit the most accurate opinion and options from one or more countries for your review

Consult Privately

Consult with a certified specialist privately on our telemedicine platform even before you decide to travel

Logistics

We handle flights, visas, transfers, and accommodation—so you can focus on your health.

Recovery

Our In-house rehabilitation service packages to better your recovery and treatment outcome

Other Popular Countries for CAR-T

Our network connects you with the leading medical tourism destinations globally, offering a wide range of cities, top doctors, and flexible pricing options.

Italy
United Kingdom
Malaysia
Vietnam

Frequently Asked Questions

A. Many hospitals in Singapore perform CAR-T. The top hospitals for CAR-T in Singapore include the following:

  1. OncoCare Cancer Centre
  2. Mount Elizabeth Hospital

A. The patient's recovery may differ based on several factors. After being discharged, a patient is expected to remain in the country for approximately thirty days on average, but this can vary depending on the patient's health condition. The patient has evaluations and consultations during this period. This ensures the patient is safe to return and that the treatment was successful.

A. In addition to the CAR-T therapy cost, patients may have to pay additional daily charges for services such as meals and other facilities during their stay. The extra charges may start from USD 150 per person.

A. The following are some of the best cities for CAR-T in Singapore:

  • Singapore

A. After a CAR-T, patients typically stay in the hospital for two or more days, depending on their condition, to receive the necessary care and monitoring. The patient is closely watched during recovery, and control tests are run to ensure everything is in order. Physiotherapy sessions are also scheduled during hospital recovery if necessary.

A. Hospitals in Singapore offering CAR-T therapy are highly regarded for their advanced medical facilities and exceptional patient care. The rating is usually based on different parameters such as the attitude of the nurses, cleanliness, quality of food, comfort of hospital rooms, and pricing policy, as CAR-T therapy can be expensive.

A. Some of the best doctors for CAR-T in Singapore are:

  1. Dr. Lim Siew Kuan
  2. Dr. Ronny Tan Ban Wei
  3. Dr. Ong Kong Wee
  4. Dr. Sam Peh Oon Hui
  5. Dr. Charles Tsang
  6. Dr. Dennis Koh

A. The type of cancer being treated is one of the factors that can affect the success rate of CAR-T (Chimeric Antigen Receptor T-cell) treatment.

For relapsed or refractory B-cell lymphoma, the long-term success rate of CAR T-cell therapy in Singapore is between 30–40%. The success rate for B-cell Acute Lymphoblastic Leukemia (ALL) that has relapsed or is refractory is greater than 50%.

CAR T-cell therapy has demonstrated encouraging outcomes in treating lymphoma and blood tumours. It can offer a better survival advantage than conventional chemotherapy, especially for relapsed or refractory blood cancers.

A. After receiving an infusion, patients may stay in the hospital for up to two weeks, and they should prepare for a two to three-month risk and recovery. Patients are assessed for side effects and therapy response during this period. Stays in hospitals to treat problems are common during this time. During the first 30 days following CAR T-cell infusion, patients must stay close to the medical facility for routine follow-up care.

A. Yes, several pre-operative tests and evaluations are necessary to determine your eligibility and ensure you are in the best possible condition for CAR-T (Chimeric Antigen Receptor T-cell) therapy.

  1. Blood Tests: Because CAR-T therapy can impact your immune system, these are essential for evaluating your general health, blood cell counts, and organ function.
  2. Cancer Cell Genetic Testing: You can determine whether CAR-T therapy is appropriate by looking for particular markers or genetic changes in your cancer cells.
  3. Heart Function Tests: Tests to assess the condition of your heart are crucial because CAR-T therapy can cause issues that could strain it.
  4. Tests of Lung Function: These examinations evaluate your lungs' capacity to provide your body with oxygen and ensure you're healthy enough to manage any respiratory side effects from CAR-T therapy. Infection Screening: Screening for infections (such as HIV, hepatitis B and C, and tuberculosis) is necessary to prevent problems because CAR-T therapy can impair your immune system.
  5. Imaging Examinations: Imaging tests determine the extent and size of your malignancy.
  6. Assessment of Neurology: Given CAR-T therapy's potential for neurological side effects, a neurological examination is recommended.

A. Whether CAR-T (Chimeric Antigen Receptor T-cell) therapy is right for you depends on several factors related to your medical condition, overall health, and response to previous treatments. Here are some factors to consider when determining if CAR-T therapy is appropriate for you:

  • Type of Cancer: CAR-T therapy is primarily used for certain blood cancers like lymphoma, leukaemia, and multiple myeloma. If you have one of these conditions and your cancer is relapsed
  • Previous Treatments: CAR-T therapy is often used after other treatments like chemotherapy, radiation, or stem cell transplants have failed. If you have exhausted other options, CAR-T could be considered the next step.
  • Health and Medical History: Your overall health plays a key role in determining whether CAR-T suits you.
  • Age: The suitability of CAR-T therapy will depend on your general health and any age-related risks, even though it has been effectively utilised in various age groups.
  • Access to CAR-T Therapy Centers: Because CAR-T therapy is a customised, sophisticated treatment that requires close supervision and skilled management, it needs a specialist medical facility.

A. Chimeric Antigen Receptor T-cell (CAR-T) therapy can have several risks and complications, including:

  1. Cytokine release syndrome (CRS): The most common side effect of CAR-T therapy is cytokine release syndrome (CRS), which peaks in the first two weeks T-cells activate and produce cytokines that cause an immune system reaction. Symptoms include high fever, low blood pressure, and hypoxia, and can impact several organs.
  2. Neurologic toxicities: Also referred to as CAR-related encephalopathy syndrome (CRES), this condition can result in a variety of symptoms, including disorientation, seizures, and trouble speaking or moving.
  3. Blood disorders: These can include anaemia and thrombocytopenia (low platelet count).
  4. Infections: Infections are more likely to occur, particularly in the initial weeks following treatment.
  5. Tumor lysis syndrome (TLS): Tumor lysis syndrome (TLS) may result. When significant levels of phosphate, potassium, and nucleic acids are released into the bloodstream following an effective cancer treatment.

Additional side effects consist of:

  • Breathing difficulties
  • Extreme diarrhoea, vomiting, or nausea
  • Feeling lightheaded or dizzy
  • A headache
  • Rapid heartbeat
  • Feeling very tired
  • Muscle and/or joint pain

A. Several variables, such as your general health, how well you tolerate the treatment, and any possible side effects, might affect how long you stay in the hospital following CAR-T (Chimeric Antigen Receptor T-cell) therapy. In Singapore, the average length of hospitalisation following CAR-T therapy is two to four weeks.

Here's what to expect:

  1. You might be discharged sooner if you're stable and have no serious difficulties.
  2. To ensure proper management of side effects, patients may, however, stay in the hospital for a lengthier amount of time.
  3. As Per your hospital's policies, you may be released when You live within a one to two-hour drive of the hospital
  4. You have a full-time caregiver at your house.
  5. For the first 30 days following your treatment, you need to plan on staying close to the medical institution for routine follow-up care.

A. It may take a few weeks or months to recover from CAR T-cell therapy, and you should expect to have follow-up appointments to check in with your medical team. Here are a few pointers to look upon following the treatment:

  • Side effects

During the healing process, you must prepare for feeling weak, exhausted, and lost appetite. Additionally, you could struggle with memory, focus, confusion, planning, or staying organised.

  • Monitoring

You will be continuously watched for neurological abnormalities, fever, and infection symptoms. If these symptoms appear, the medical care team will assist.

  • Follow-up consultations

Follow-up consultations with the medical team will be needed.

  • Activities

The body will need a little time to heal properly before returning to regular activities.

  • Fatigue

It may take several months for fatigue to get better. You must listen to your body, pace yourself accordingly, and divide everyday tasks into small phases.

  • Strength and fitness

During treatment, your strength and level of fitness may decrease. You can ask for assistance from a physiotherapist to build up your strength or to return to exercise.

Author

Dr. Vishwas Kaushik

MBBS, MD

5 Years of Experience

Dr. Vishwas Kaushik is a qualified medical professional holding an MBBS from the prestigious Belgorod State University, Russia, with a strong foundation in clinical medicine and healthcare practice. His comprehensive medical training has equipped him with a profound understanding of evidence-based clinical practices, patient-centered care, and the evolving landscape of modern medicine. With a keen interest in medical research and scientific communication, he consistently translates complex clinical concepts into clear, accurate, and accessible content for diverse audiences. His work reflects a deep commitment to advancing medical knowledge, delivering impactful healthcare insights, and bridging the gap between clinical expertise and accessible medical communication.. View More

Reviewer

Dr Prateek Varshney

Surgical Oncologist

15 Years of Experience

Dr. Prateek Varshney is a renowned Surgical Oncologist. He has experience of more than 15+ years in surgical Oncology. He is currently practicing as a consultant at Metro Mass Hospital and Cancer Institute. He was also previously associated as a consultant with Sir Ganga Ram Hospital and as a professor at Gujarat Cancer Research Institute. View More